Last reviewed · How we verify
Jadran Galenski laboratorij d.d. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
3 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Vizol S DIGI EYE eye drops | Vizol S DIGI EYE eye drops | phase 3 | prostaglandin analog | PGF2α receptor | Ophthalmology | |
| Vizol S LIPID BALANCE eye drops | Vizol S LIPID BALANCE eye drops | phase 3 | eye lubricant | Ophthalmology | ||
| ophthalmic saline eye drops | ophthalmic saline eye drops | phase 3 | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 3
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Allergan · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Jadran Galenski laboratorij d.d.:
- Jadran Galenski laboratorij d.d. pipeline updates — RSS
- Jadran Galenski laboratorij d.d. pipeline updates — Atom
- Jadran Galenski laboratorij d.d. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Jadran Galenski laboratorij d.d. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jadran-galenski-laboratorij-d-d. Accessed 2026-05-16.